


# Author's Accepted Manuscript

Racial Disparities in the Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis as Urate-Lowering Drug Adverse Events in the USRace and Severe Urate-Lowering Drug Adverse Events

Na Lu, Sharan K. Rai, Robert Terkeltaub, Seoyoung C. Kim, Mariano E. Menendez, Hyon K. Choi



PII: S0049-0172(16)30004-X  
DOI: <http://dx.doi.org/10.1016/j.semarthrit.2016.03.014>  
Reference: YSARH51041

To appear in: *Seminars in Arthritis and Rheumatism*

Received date: 2 February 2016  
Revised date: 27 March 2016  
Accepted date: 28 March 2016

Cite this article as: Na Lu, Sharan K. Rai, Robert Terkeltaub, Seoyoung C. Kim, Mariano E. Menendez and Hyon K. Choi, Racial Disparities in the Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis as Urate-Lowering Drug Adverse Events in the USRace and Severe Urate-Lowering Drug Adverse Events, *Seminars in Arthritis and Rheumatism*, <http://dx.doi.org/10.1016/j.semarthrit.2016.03.014>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Racial Disparities in the Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis as Urate-Lowering Drug Adverse Events in the US

<sup>1</sup>Na Lu, MPH, <sup>2</sup>Sharan K. Rai, BSc, <sup>3</sup>Robert Terkeltaub, <sup>4</sup>Seoyoung C. Kim, MD, ScD, <sup>5</sup>Mariano E. Menendez, MD, <sup>6</sup>Hyon K. Choi, MD, DrPH

Authors Affiliations:

<sup>1</sup>Boston University School of Medicine, Clinical Epidemiology Research and Training Unit, Boston, MA, USA

<sup>2</sup>Arthritis Research Canada, Vancouver, British Columbia, Canada; Department of Experimental Medicine, University of British Columbia, Vancouver, British Columbia, Canada

<sup>3</sup>Division of Rheumatology, Allergy and Immunology, VAMC/UCSD, La Jolla, CA, USA

<sup>4</sup>Division of Pharmacoepidemiology and Pharmacoeconomics, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston MA USA

<sup>5</sup>Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

<sup>6</sup>Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Running title: Race and Severe Urate-Lowering Drug Adverse Events

Key words: Race, Allopurinol, Urate-Lowering Therapy, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Gout

Competing Interests: HKC has served as a consultant for Takeda Pharmaceuticals and Astra-Zeneca Pharmaceuticals and the VA Research Service. SCK has received research grants to the Brigham and Women's Hospital from Pfizer, AstraZeneca, Lilly, and Genentech for unrelated studies.

Corresponding Author:

Hyon K. Choi, MD, DrPH  
Professor of Medicine, Harvard Medical School  
Division of Rheumatology, Allergy, and Immunology  
Department of Medicine, Massachusetts General Hospital  
55 Fruit Street, Bulfinch 165, Boston, MA 02114  
Tel: 617-726-5650 Fax: 617-726-2872  
E-mail: hchoi@partners.org

Download English Version:

<https://daneshyari.com/en/article/5584014>

Download Persian Version:

<https://daneshyari.com/article/5584014>

[Daneshyari.com](https://daneshyari.com)